On the morning of May 22nd, the signing ceremony for the appointment of the director of Academic Committee of Shandong Anticancer Drug Engineering Laboratory (below as "SADEL") was held in Shandong Shenogen Pharmaceutical Co., Ltd. in Laiwu City, Shandong Province: Changxiao Liu, a member of the Chinese Academy of Engineering, was appointed as the Director of the Academic Committee of the laboratory. The ceremony for the appointment of the director of the Academic Committee of the Shandong Anticancer Drug Engineering Laboratory was presided over by Baoling Ma, the secretary of the Laicheng District Committee of Laiwu City. Guiai Zhang, the Vice Mayor of Laiwu City, attended the ceremony and delivered a speech. The chairman and CEO of Beijing Shenogen Pharmaceutical Co., Ltd., and the chairman of Shandong Shenogen Pharmaceutical Co., Ltd., Dr. Kun Meng, delivered the certificate of appointment for academician Changxiao Liu. The Secretary of the Party Committee of Laicheng Industrial Park and the Director of the Management Committee Hongjun Sang, the Minister of Organization Department of Laicheng District Weiying Han; the Vice President of Beijing Shenogen Pharmaceutical Co., Ltd. Yongmao Liu, the Senior Vice President Xiao Shang and Yunxiang Zhu attended the signing ceremony.

The Shandong Provincial Anti-tumor Drug Engineering Laboratory is a provincial laboratory established by Shandong Shenogen Pharmaceutical Co., Ltd. It was recognized by the Shandong Provincial Development and Reform Committee and is one of 15 provincial-level engineering laboratories (engineering research centers) in Laiwu City.

Academician Changxiao Liu, a current Doctoral advisor, honorary president of Tianjin Pharmaceutical Research Institute, the Director of the State Key Laboratory of drug delivery technology and pharmacokinetics, member of the National Committee for Research and Development of New Drugs and GLP Expert Committee, and the Executive Director of the Chinese Pharmacology Society. Academician Changxiao Liu has been engaged in pharmacokinetics research for more than 50 years. He is one of the academia pioneers and leaders in pharmacokinetics research in China and has undertaken more than 50 major national and provincial scientific and technological projects and the pharmacokinetic research of about 150 innovative drugs. He has won more than 40 international, national and provincial scientific and technological achievement awards.

Prior to the signing ceremony, Academician Changxiao Liu visited the manufacturing plant, pilot plant and the Party education base of Shandong Shenogen Pharmaceutical Co., Ltd.. He discussed with Dr. Kun Meng, the chairman of the company, on the development status and prospects of the current Chinese anti-cancer drugs, and delivered highly complimentary remarks about the Shenogen’s effort on the development and production of innovative medicines for tumors and immune inflammations.

At the signing ceremony, Kun Meng stated that as one of the leaders in domestic tumor immunotherapy drugs, Shenogen has gathered innovative advantages in new technologies, new targets, new products and IPs in the field of small molecules, oncolytic viruses, and immune checkpoint PD-L1. Shenogen has great pipelines, including Icaritin, Icaritin combined with oncolytic virus, Icaritin combined with PD-L1, SNG1005, which already started or is about to start Phase III trials. Dr. Liu’s appointment as the director of the academic committee of the Shandong Anticancer Drug Engineering Laboratory will achieve strong alliances, mutual benefit, and win-win results. This will play an important role in promoting major technological breakthroughs in the research and development of anti-tumor drugs in Shandong Shenogen. ”